Low-Cost and Scalable Platform with Multiplexed Microwell Array Biochip for Rapid Diagnosis of COVID-19

发布日期:2021-11-09 16:12:02   作者 :常凌乾    浏览量 :155
常凌乾 unknown 发布日期:2021-11-09 16:12:02  
155

Coronavirus disease 2019 (COVID-19) has been a life-threatening pandemic caused by SARS-CoV-2 [1, 2]. It consists of four structural proteins and a single-stranded RNA as the genetic materials [3]. The rapid transmission of the virus among human beings has caused wide threats to the public health [4- 8]. Up to August 23, 2020, the disease has spread to more than 200 countries, infected over 23.2 million people, and resulted in at least 800,000 deaths [9]. There is an urgent need on techniques for rapid and accurate detection of SARS-CoV-2 to inhibit its further spreading. Point-of-care testing(POCT) platforms with advantages of low-cost, easy operation, and high sensitivity/specificity are broadly applicable to daily life [10, 11].

The symptoms of the patients with the infection of COVID-19 are nonspecific, so various diagnostic methods have been developed accordingly [12-17]. To rapidly screen the subject infected with COVID-19, nucleic acid testing(NAT) based on the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is now applied as a clinical-acceptable standard [18, 19]. Till now, RT-qPCR has been proved to be highly sensitive and specific [20, 21]. However, its dependence on expensive thermocycler and read-out systems limits the application, especially in some scenarios where the exponential increase of the infected

-
CoV
RT
邮箱:John.Zhang@g-biohub.com
地址:深圳市龙华区观澜街道新澜社区观光路1301-76号银星智界二期1号楼B214
北京载愈生物科技有限公司 版权所有 © 2021 EdiGene Inc. all rights reserved.
管理网站 举报反馈 网站统计